Costanza Brunella, Turtoi Andrei, Bellahcène Akeila, Hirano Touko, Peulen Olivier, Blomme Arnaud, Hennequière Vincent, Mutijima Eugene, Boniver Jacques, Meuwis Marie-Alice, Josse Claire, Koopmansch Benjamin, Segers Karin, Yokobori Takehiko, Fahmy Karim, Thiry Marc, Coimbra Carla, Garbacki Nancy, Colige Alain, Baiwir Dominique, Bours Vincent, Louis Edouard, Detry Olivier, Delvenne Philippe, Nishiyama Masahiko, Castronovo Vincent
Metastasis Research Laboratory, GIGA Cancer, University of Liège, Liège, Belgium.
Laboratory for Analytical Instruments, Gunma University Graduate School of Medicine, Gunma, Japan.
Oncotarget. 2018 Jan 31;9(12):10665-10680. doi: 10.18632/oncotarget.24366. eCollection 2018 Feb 13.
The identification of diagnostic and prognostic biomarkers from early lesions, measurable in liquid biopsies remains a major challenge, particularly in oncology. Fresh human material of high quality is required for biomarker discovery but is often not available when it is totally required for clinical pathology investigation. Hence, all OMICs studies are done on residual and less clinically relevant biological samples. Here after, we present an innovative, simple, and non-destructive, procedure named EXPEL that uses rapid, pressure-assisted, interstitial fluid extrusion, preserving the specimen for full routine clinical pathology investigation. In the meantime, the technique allows a comprehensive OMICs analysis (proteins, metabolites, miRNAs and DNA). As proof of concept, we have applied EXPEL on freshly collected human colorectal cancer and liver metastases tissues. We demonstrate that the procedure efficiently allows the extraction, within a few minutes, of a wide variety of biomolecules holding diagnostic and prognostic potential while keeping both tissue morphology and antigenicity unaltered. Our method enables, for the first time, both clinicians and scientists to explore identical clinical material regardless of its origin and size, which has a major positive impact on translation to the clinic.
从早期病变中识别可在液体活检中检测到的诊断和预后生物标志物仍然是一项重大挑战，尤其是在肿瘤学领域。生物标志物发现需要高质量的新鲜人类材料，但在临床病理检查完全需要这些材料时，往往无法获得。因此，所有组学研究都是在残留的、临床相关性较低的生物样本上进行的。在此，我们提出了一种创新、简单且无损的程序，名为EXPEL，它使用快速、压力辅助的组织间液挤压技术，在保留样本用于完整常规临床病理检查的同时，还能进行全面的组学分析（蛋白质、代谢物、微小RNA和DNA）。作为概念验证，我们已将EXPEL应用于新鲜采集的人类结直肠癌和肝转移组织。我们证明，该程序能够在几分钟内有效地提取出具有诊断和预后潜力的多种生物分子，同时保持组织形态和抗原性不变。我们的方法首次使临床医生和科学家能够探索相同的临床材料，而无论其来源和大小如何，这对转化到临床具有重大的积极影响。
